U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07171203) titled 'Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor' on Sept. 05.
Brief Summary: The goal of this clinical trial is to learn what dose of the drug fampridine can be given safely together with imatinib (Gleevec) in patients with gastrointestinal stromal tumor (GIST) with a DNA mutation in exon 11 of the KIT gene.
The main questions this study aims to answer are:
* What is the maximum dose of fampridine that can be given safely together with imatinib (Gleevec)?
* Is the combination of the two drugs efficacious against the tumor?
Participants will:
* Take the drugs before tumor surgery (neoadjuvant tr...